Skip to main content
. Author manuscript; available in PMC: 2015 Jun 28.
Published in final edited form as: Cancer Lett. 2014 Mar 21;348(0):156–166. doi: 10.1016/j.canlet.2014.03.016

Figure 6. Pancreatic cancer cells treated with either TRAIL or triptolide or their combination induce a conformational change in BAX and cleavage of Bid.

Figure 6

A. Total BAX expression was detected by western blot with anti-BAX (N20) antibody in MIA PaCa-2 and S2-VP10 cells treated with TRAIL or triptolide or both. β-actin expression was used as loading control.

B. Conformational change in BAX protein was detected by western blot with anti-BAX (6A7) antibody in MIA PaCa-2 and S2-VP10 cells treated with TRAIL or triptolide or both. β-actin expression was used as loading control.

C. Mitochondrial translocation of BAX was evaluated with confocal microscopy. BAX (N20) (green) colocalizes with mitochondrial (MitoTracker red) in TRAIL/triptolide treated MIA PaCa-2 cells, suggesting a translocation of BAX from cytosol to the mitochondria. Scale bar, 10 micron/L.

D. Bid cleavage was evaluated by western blot with anti-Bid antibody in MIA PaCa-2 and S2-VP10 cells treated with TRAIL or triptolide or both. β-actin expression was used as loading control.